ClearPoint Neuro Stock
ClearPoint Neuro, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Joseph Michael Burnett
- Employees
- 172
- Market cap
- $277 M
- IPO
- 22/05/2012
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core…
ClearPoint Neuro stock: price history
1D
-5.9%
1W
-13.5%
1M
-32.3%
6M
-23.1%
YTD
-33.7%
1Y
-64.1%
2Y
-24.3%
5Y
-49.5%
10Y
+108.5%
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~24% stronger price swings than usual
Ask the agents about ClearPoint Neuro
Analyst assessment of ClearPoint Neuro
PRICE TARGET LOW
US$22.00
CONSENSUS
US$23.50
MEDIAN
US$23.50
PRICE TARGET HIGH
US$25.00
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 18/06/2026
ClearPoint Neuro stock metrics
P/E
-7.69
P/B
25.13
EV/EBITDA
-11.5
RETURN ON EQUITY
-105.2%
NET MARGIN
-104.2%
DEBT/EQUITY
5.93
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
86.2%
FLOAT SHARES
26,282,442
AVG. DAILY VOLUME (30D)
729,485
Insider transactions (SEC)
FLETCHER R JOHN
Richards Timothy T.
BURNETT JOSEPH
Richards Timothy T.
FLETCHER R JOHN
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -5.9%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about ClearPoint Neuro stock
What does ClearPoint Neuro do?
ClearPoint Neuro, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Joseph Michael Burnett, the company employs around 172 people.
The IPO was on 22/05/2012; the stock trades on NASDAQ under the ticker CLPT.
What do analysts say about ClearPoint Neuro stock?
3 analysts rate the stock, the consensus is Buy (as of 18/06/2026).
The average price target is US$23.50, ranging from US$22.00 to US$25.00, with a median of US$23.50.
This is an external assessment, not a statement by Market Jury.
When does ClearPoint Neuro report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly 24% stronger than usual.
Does ClearPoint Neuro pay a dividend?
No, ClearPoint Neuro currently does not pay a dividend.
Which stocks are comparable to ClearPoint Neuro?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get ClearPoint Neuro stock analyzed?
Clicking "Analyze stock" lets five strategies assess ClearPoint Neuro against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.